Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

2019 The Lancet 2,355 citations

Keywords

DocetaxelMedicineEpirubicinCapecitabineOxaliplatinFluorouracilInternal medicineChemotherapyGastroenterologyPopulationMucositisSurgeryCancerOncologyColorectal cancerCyclophosphamide

Affiliated Institutions

Related Publications

A Predictive Model for Aggressive Non-Hodgkin's Lymphoma

The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and...

1993 New England Journal of Medicine 4882 citations

Publication Info

Year
2019
Type
article
Volume
393
Issue
10184
Pages
1948-1957
Citations
2355
Access
Closed

External Links

Citation Metrics

2355
OpenAlex

Cite This

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk et al. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. The Lancet , 393 (10184) , 1948-1957. https://doi.org/10.1016/s0140-6736(18)32557-1

Identifiers

DOI
10.1016/s0140-6736(18)32557-1